Therapeutic principles of primaquine against relapse of Plasmodium vivax malaria

1st International Conference on Tropical Medicine and Infectious Diseases (ICTROMI) Faculty of Medicine Universitas Sumatera Utara

Baird, J.K.^1,2

Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Indonesia^1

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Jakarta, United Kingdom^2

关键词: Human liver;    P. vivax;    Plasmodium falciparum;    Plasmodium vivax;   

Others  :  https://iopscience.iop.org/article/10.1088/1755-1315/125/1/012098/pdf
DOI  :  10.1088/1755-1315/125/1/012098

来源: IOP

【 摘 要 】

Plasmodium vivax causes tens of millions of clinical attacks annually all across the malarious globe. Unlike the other major cause of human malaria, Plasmodium falciparum, P. vivax places dormant stages called hypnozoites into the human liver that later awaken and provoke multiple clinical attacks in the weeks, months, and few years following the infectious anopheline mosquito bite. The only available treatment to prevent those recurrent attacks is primaquine (hypnozoitocide), and it must be administered with the drugs applied to end the acute attack (blood schizontocides). This paper reviews the therapeutic principles of applying primaquine to achieve radical cure of acute vivax malaria.